AllPennyStocks.com Citizens Says FDA’s 'Unexpected' Phase 3 Request Clouds Mirum’s Near-Term Outlook – MIRM Stock Crashes 15%
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

Citizens Says FDA’s 'Unexpected' Phase 3 Request Clouds Mirum’s Near-Term Outlook – MIRM Stock Crashes 15%

The firm said the U.S. Food and Drug Administration’s request for an additional Phase 3 trial of Volixibat to treat a liver disease is expected to delay the program.

Other Penny Stock Movers

When Design Thinking Meets the AI Canvas
Peru Silver Restart Jumps 15% After First Concentrate Yields 29k oz Ag
PNG Explorer Rallies 18% as Drill Bit Hits High-Grade Gold Target
Most Popular
{{ index + 1 }}


Back to Top